<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655018</url>
  </required_header>
  <id_info>
    <org_study_id>VITENAFLD</org_study_id>
    <nct_id>NCT00655018</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)</brief_title>
  <acronym>VITENAFLD</acronym>
  <official_title>Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bambino Gesù Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      No proven treatment exists for nonalcoholic fatty liver disease (NAFLD) in children and&#xD;
      adolescents. We aim to determine the efficacy of lifestyle intervention with or without&#xD;
      antioxidant therapy in pediatric NAFLD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      InChildren or adolescents with well-characterized and liver biopsy confirmed NAFLD will be&#xD;
      enrolled. They will be randomized to treatment with alpha tocopherol 600 IU/d plus ascorbic&#xD;
      acid 500 mg/d (n=45) or an identical placebo (n=45) given orally. All patients will be&#xD;
      included in a lifestyle intervention program consisting of a diet tailored on the individual&#xD;
      requirements and physical exercise. The body mass index (BMI) and BMI Z-score will be&#xD;
      calculated . Obesity was defined for a percentile of BMI ≥ 95th percentile for age and gender&#xD;
      .&#xD;
&#xD;
      Patients will undergo a medical evaluation every three months during the 24-month study&#xD;
      period. Laboratory tests including liver enzymes and lipids will be repeated at 3-month&#xD;
      intervals during the 24-month study duration. Ultrasonography of the liver will be repeated&#xD;
      at the end of the study period.&#xD;
&#xD;
      Evaluation of Glucose Metabolism and Insulin Sensitivity A 2-hour oral glucose tolerance test&#xD;
      (OGTT) will be performed at baseline and repeated at 24 mo. of treatment with the standard&#xD;
      1.75 g of glucose per kg, or maximum of 75 g. Glucose tolerance status will be determined&#xD;
      according to the classification of the American Diabetes Association in which fasting plasma&#xD;
      glucose (FPG) levels up to 99 mg/dl are considered normal; impaired fasting glucose (IFG) is&#xD;
      defined by a FPG of 100-125 mg/dl; impaired glucose tolerance (IGT) is defined by a 2-hour&#xD;
      plasma glucose of 140-199 mg/dl; diabetes mellitus is defined by a FPG ≥126 mg/dl, or a&#xD;
      2-hour plasma glucose ≥200 mg/dl .&#xD;
&#xD;
      The degrees of insulin resistance and sensitivity will be determined, respectively, by the&#xD;
      homeostatic model assessment (HOMA-IR) using the formula: IR = (insulin*glucose)/22.5; and by&#xD;
      the insulin sensitivity index (ISI) derived from OGTT using the formula: ISI = (10,000/square&#xD;
      root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]).&#xD;
&#xD;
      Liver biopsy Liver biopsy will be performed at baseline and repeated at 24 mo. of treatment.&#xD;
      Biopsies will be routinely processed and analyzed as described previously. Pre- and&#xD;
      post-treatment liver biopsies will be reviewed and scored by a single pathologist who will be&#xD;
      unaware of the assigned treatment, patients' clinical and laboratory data, and liver biopsy&#xD;
      sequence. The main histological features of NAFLD including steatosis (macro and&#xD;
      microvesicular), inflammation (portal and lobular), hepatocyte ballooning, and fibrosis will&#xD;
      be scored using the scoring system for NAFLD recently proposed by the NIH-sponsored NASH&#xD;
      Clinical Research Network.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum levels of aminotransferases</measure>
    <time_frame>months 12 and 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver histology (inflammation and fibrosis)</measure>
    <time_frame>month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Inflammation</condition>
  <condition>Fibrosis</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Vitamin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin treatment (alpha tocopherol plus ascorbic acid)</intervention_name>
    <description>alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
    <arm_group_label>Vitamin group</arm_group_label>
    <other_name>alpha-tocoferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  persistently elevated serum aminotransferase levels,&#xD;
&#xD;
          -  diffusely echogenic liver on imaging studies suggestive of fatty liver, and&#xD;
&#xD;
          -  biopsy consistent with the diagnosis of NAFLD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hepatic virus infections (HCV RNA-PCR negative),&#xD;
&#xD;
          -  Hepatitis A, B, C, D, E and G,&#xD;
&#xD;
          -  cytomegalovirus and Epstein-Barr virus,&#xD;
&#xD;
          -  alcohol consumption,&#xD;
&#xD;
          -  history of parenteral nutrition,&#xD;
&#xD;
          -  and use of drugs known to induce steatosis (e.g. valproate, amiodarone or prednisone)&#xD;
             or to affect body weight and carbohydrate metabolism.&#xD;
&#xD;
          -  Autoimmune liver disease, metabolic liver disease, Wilson's disease, and&#xD;
             a-1-antitrypsin-associated liver disease were ruled out using standard clinical,&#xD;
             laboratory and histological criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerio Nobili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bambino Gesù Hospital and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Of HepatoGastoEnterology and Nutrition, Liver Unit</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.ospedalebambinogesu.it/</url>
    <description>Hospital's web site</description>
  </link>
  <reference>
    <citation>Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005 May;100(5):1082-90.</citation>
    <PMID>15842582</PMID>
  </reference>
  <reference>
    <citation>Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, Capuano G, Migliaro F. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004 Jan;38(1):48-55.</citation>
    <PMID>14676594</PMID>
  </reference>
  <reference>
    <citation>Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000 Jun;136(6):734-8.</citation>
    <PMID>10839868</PMID>
  </reference>
  <results_reference>
    <citation>Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006 Dec;24(11-12):1553-61.</citation>
    <PMID>17206944</PMID>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2008</study_first_posted>
  <last_update_submitted>April 8, 2008</last_update_submitted>
  <last_update_submitted_qc>April 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Valerio Nobili, MD</name_title>
    <organization>Bambino Gesù Hospital and Research Institute</organization>
  </responsible_party>
  <keyword>Non-Alcoholic Fatty Liver Disease (NAFLD)</keyword>
  <keyword>Non-Alcoholic Steatohepatitis (NASH)</keyword>
  <keyword>Liver histology</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Alpha-tocopherol</keyword>
  <keyword>ascorbic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

